MGRO is an extremely small and speculative play with a market cap at only $73.59M. The balance sheet has virtually no debt and a net cash position of $2.5M. There is not much for us to analyze fundementally yet due to how early stage it is. MGRO did pick up a new commercial license with Bayer just a few months ago which is a positive development. The stock is up11% YTD but down 57% in a year. Cash flow has been negative since inception, and more capital is going to be needed. Insiders own 12% and have been buyers in the past six months. It has no revenue but one analyst covers it (Noble Capital). The Bayer deal allows Bayer to evaluate MGRO's technology in certain soil applications. It is a good technical valuation but we would like to see revenue here. Overall: very high risk and hard to strongly endorse.
5i Research Answer: